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Background: Several countries have introduced generic substitution, but few studies have assessed its effect on
refill adherence. This study aimed to analyse whether generic substitution influences refill adherence to statin
treatment.
Methods: Between 1 July 2006 and 30 June 2007, new users of simvastatin (n = 108,806) and atorvastatin (n = 7,464)
were identified in the Swedish Prescribed Drug Register . The present study included atorvastatin users as an unexposed
control group because atorvastatin was patent-protected and thus not substitutable. We assessed refill adherence using
continuous measure of medication acquisition (CMA). To control for potential confounders, we used analysis of
covariance (ANCOVA). Differences in CMA associated with generic substitution and generic substitution at
first-time statin purchase were analysed.
Results: Nine of ten simvastatin users were exposed to generic substitution during the study period, and
their adherence rate was higher than that of patients without substitution [84.6% (95% CI 83.5-85.6) versus
59.9% (95% CI 58.4-61.4), p < 0.001]. CMA was higher with increasing age (60–69 years 16.7%, p < 0.0001 and
70–79 years 17.8%, p < 0.0001, compared to 18–39 years) and secondary prevention (12.8%, p < 0.0001). CMA
was lower among patients who were exposed to generic substitution upon initial purchase, compared to
those who were exposed to a generic substitution subsequently [80.4% (95% CI 79.4-90.9) versus 89.8%
(88.7-90.9), p < 0.001]. This difference decreased when those with only one statin purchase were excluded.
Conclusions: Statin refill adherence was higher among patients who exposed to generic substitution
compared to those who were not. Increasing age and previous cardiovascular disease affected refill
adherence.
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Based on register data on dispensed medicines, previous
studies reported an indirect measure of statin refill ad-
herence totalling more than 80% [1,2]. Refill adherence
is a valid estimate of adherence to medication [3]. Good
adherence to statin treatment associates with signifi-
cantly lower risks for cardiovascular disease (CVD)
and mortality [4].* Correspondence: karolina.a.sundell@gu.se
1Section of Social Medicine and Epidemiology, Department of Public Health
and Community Medicine, Institute of Medicine, The Sahlgrenska Academy
at University of Gothenburg, PO Box 453, 405 30 Gothenburg, Sweden
2Nordic School of Public Health, Gothenburg, Sweden
© 2014 Trusell and Andersson Sundell; license
of the Creative Commons Attribution License
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.Although few studies have explored whether generic
substitution affects refill adherence, some reports sug-
gest that patients find it more difficult to keep track of
their medication after generic substitution [5,6]. How-
ever, a small proportion of patients reported intake er-
rors following generic substitution [5], most commonly
they simultaneously used two different products with
the same active pharmaceutical ingredient. Some reports
express concern that generics have lower quality than
brand-name products [7,8]. However, a survey reported
that only a small group of the patients thought that ge-
nerics caused more side effects than their brand-name
equivalent [8].e BioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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generic substitution affect refill adherence report that
adherence is higher among patients who start treatment
with generics, compared to those who start with brand-
name drugs [7,9]. We wanted determine whether this
pattern of adherence applies to refill adherence for sta-
tins, using a method validated in the Swedish setting.
Thus, this study used continuous measure of medica-
tion acquisition (CMA) to analyse whether generic
substitution influences refill adherence to statin therapy.
We also aimed to assess to what extent socioeconomic
and clinical characteristics affect refill adherence.
Methods
Study population and study period
Between 1 July 2006 and 30 June 2007, new users of sim-
vastatin (ATC code C10AA01) and atorvastatin (ATC
code C10AA05) were identified in the Swedish Prescribed
Drug Register (SPDR) [10]. During the study period, index
date was defined as the date each individual purchased a
statin for the first time. Thus, a new user was defined as
an individual who did not fill any prescriptions for
lipid-lowering treatment (ATC-code C10) during the
12 months preceding the index date. The present study
included atorvastatin as an unexposed control group
because no generic substitute for atorvastatin was avail-
able during the study period. We followed all participants
until death, emigration, or for a maximum of two years
after the index date. If an unrecorded death occurred dur-
ing follow up, we assumed that death occurred on the
15th of the specified month (n = 22), or on July 1st if only
the year was specified (n = 2).
We excluded individuals who (i) were younger than
18 years of age at index date; (ii) received multi-dose
dispensed drugs during the study period; (iii) were regis-
tered as deceased prior to the index date; (iv) purchased
more than one statin substance on their index date
(n = 15); or (v) died or emigrated on their index date
(n = 2). Switching from simvastatin to another statin
was allowed because such switches are a normal part
of clinical practice. However, we excluded individuals
who switched statin substances four or more times
during the study period (n = 252).
Data sources
SPDR data on dispensed drugs included all prescriptions
dispensed in Sweden during the study period [10], and
information about (i) the dispensed drug (name, sub-
stance, drug type, strength, and amount); (ii) the patient
(age, sex, and place of residence); (iii) the prescriber
(profession and workplace); (iv) the price paid by the pa-
tient; (v) the level of reimbursement; and (vi) the date of
issue and dispensing. Recorded as free text, dosage in-
structions sometimes include the indication. When thepharmacy dispensed a product other than the one pre-
scribed (due to generic substitution), information about
both products is provided.
Information about participants’ highest attained level
of education and migration background were collected
from the Swedish Longitudinal Integration Database for
Health Insurance and Labour Market Studies (LISA) on
individual-level. We obtained information about hospital
care (i.e., diagnosis codes), which was classified according
to the International Statistical Classification of Diseases
and Related Health Problems 10th revision (ICD-10) from
the Swedish National Patient Register.Exposure assessment
We defined generic substitution as not receiving the pre-
scribed product, but receiving a substitute product approved
by the Medical Products Agency. Generic substitution can
also occur if the prescribed product is unavailable at the
pharmacy. In Sweden, the prescriber and the pharmacy can
restrict generic substitution due to medical reasons or issues
related to formulation, dosage regimen, etc. In that case, the
pharmacy dispenses the prescribed product and the
Pharmaceutical Benefit Scheme (PBS) covers the full
cost included in the patients total co-payment [11]. If
the patient refuses substitution, the pharmacy attri-
butes the price of the cheapest available substitutable
product to the total PBS co-payment and the patient
pays the balance out of pocket. We considered same-
strength products from the same manufacturer identical
even if the package size differed. However, we considered
different strengths from the same manufacturer as differ-
ent products because pharmacists cannot dispense other
strength than that prescribed.
We classified exposure to generic substitution into
four groups: (i) simvastatin users who experienced gen-
eric substitution during follow-up, (ii) simvastatin users
who did not experience generic substitution due to an
active decline by the prescriber/pharmacist or the pa-
tient, (iii) simvastatin users who did not experience gen-
eric substitution but where no active decline was made
(i.e., no cheaper substitute was available), and (iv) ator-
vastatin users.Outcome measure
We calculated refill adherence using CMA [i.e., (number
of days’ supply dispensed during the study period)/(number
of days in the study period)].
A previous study reported that 98.4% of new simvastatin
users took one tablet or capsule per day [2]. Therefore, our
assumed dosage was one tablet or capsule per day. We
accounted for stockpiling of medication before the previ-
ous supply was fully consumed by adding the remaining
amount to the next purchase. When statin substances were
Table 1 Socioeconomic and clinical characteristics of
new users of simvastatin (n = 108,806) and atorvastatin
(n = 7,464)
Simvastatin Atorvastatin
Variable n % n %
Gender
Female 51,130 47.0 3,389 45.4
Male 57,676 53.0 4,075 54.6
Age (years)
18–39 2,482 2.3 284 3.8
40–49 9,696 8.9 779 10.4
50–59 25,398 23.3 1,963 26.3
60–69 37,303 34.3 2,549 34.2
70–79 25,224 23.2 1,531 20.5
80– 8,703 8.00 358 4.8
Background
Swedish 90,517 83.2 5,844 78.3
Migrant 18,289 16.8 1,620 21.7
Place of birth if foreign background
Sweden 756 4.1 85 5.2
Other Nordic country 6,495 35.5 452 27.9
Other EU27 country 3,567 19.5 373 23.0
Other European country 2,886 15.8 229 14.1
Africa 482 2.6 43 2.7
North America 186 1.0 28 1.7
South America 473 2.6 55 3.4
Asia and Oceania 2,872 15.7 296 18.3
Former Soviet Union 115 0.6 14 0.9
Unknown place of birth 457 2.5 45 2.8
Level of education
Primary school, <9 years 19,199 17.7 1100 14.7
Primary school, 9 years 9,180 8.4 707 9.5
Secondary school 40,097 36.9 2862 38.3
University, <2 years 2,962 2.7 234 3.1
University, ≥2 years 16,621 15.3 1405 18.8
Postgraduate 714 0.7 87 1.2
Unknown education level 20,033 18.4 1069 14.3
Previous disease
Cardiovascular disease 25,266 23.2 1,278 17.1
Renal disease 388 0.4 93 1.2
Both 492 0.5 40 0.5
Pharmacological diabetes treatment
Oral antidiabetics 9,798 9.0 581 7.8
Insulin 4,553 4.2 400 5.4
Combination of these 3,056 2.8 229 3.1
Total 17,407 16.0 1,210 16.2
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viously purchased substance.
To study whether generic substitution occurring some-
time during the study period affected CMA, we divided
the study population into the four groups described above.
To study whether timing of initial generic substitution
affected refill adherence, we divided simvastatin users
who had experienced generic substitution into two sub-
groups: (i) first generic substitution at index date, and
(ii) first generic substitution later on.
Two sensitivity analyses assessed the potential impact
of early discontinuation and switching on CMA. First,
we analysed the potential impact of early discontinuation
by excluding participants who filled only one prescrip-
tion. Second, we investigated the impact of switching by
analysing participants who did not switch and those who
switched (with one to three statins) separately.
Potential confounders
Potential confounders included age, sex, level of education,
migration background, number of prescription drugs used,
pharmacologically treated diabetes, and statin prescribed
for secondary prevention (i.e., diagnosed renal disease and/
or CVD). After determining age at index date, we divided
participants into five age groups: 18–39, 40–49, 50–59,
60–69, and 70–79 years of age.
We grouped highest attained level of education into
primary school, secondary school, and university degree.
We defined migrant background according to Statistics
Sweden’s alternative classification, wherein an individual
has migrant background if he/she was born outside
Sweden to two parents also born abroad, or born in
Sweden to two parents born abroad. If we could not de-
termine the birthplace of one or both parents, we as-
sumed that the parent(s) was born in the same place as
the studied individual.
We defined the number of prescription drugs pur-
chased in the year before the index date as the number
of purchased substances. Pharmacologically treated dia-
betes was defined as having purchased blood glucose-
lowering drugs (ATC-code A10) in the year before the
index date. We differentiated between insulin only (A10A)
and oral antidiabetics (A10B) taken alone or with insulin.
We also determined how many generically substituted
drugs each individual received.
Diagnoses of CVDs and renal diseases registered five
or fewer years before the index date served as indicators
for secondary prevention. CVDs included ischaemic heart
diseases (ICD-10 code I20-I25), pulmonary heart disease,
and diseases of pulmonary circulation (I26-I28), cerebro-
vascular diseases (I60-I69), and diseases of arteries, arteri-
oles, and capillaries (I70-I79). Renal diseases included
glomerular diseases (N00-N08) and codes indicating
renal failure (N17-N19) [12].
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We compared mean values using the t-test for two groups,
and used analysis of variance (ANOVA) with Bonferroni
correction to compare unadjusted means between more
than two groups. To compare adjusted means at the 95%
confidence level, accounting for potential confounders, we
used analysis of co-variance (ANCOVA) with Bonferroni
correction. We calculated 95% confidence intervals (95% CI)
in the ANOVA and ANCOVA analyses. P-values <0.05 were
considered statistically significant. All statistical analysis was
conducted using SAS statistical software version 9.3 (SAS
Institute, Cary, NC, USA).Ethical considerations
The study was approved by the Regional Ethics Commit-
tee in Gothenburg (registration reference: 284–09).Results
Study population
Among 116,270 participants, 108,806 were new users of
simvastatin and 7,464 were new users of atorvastatin
(controls). Altogether, 241 simvastatin users emigrated
and 3,090 died during follow up; among these, 120 emi-
grations and 1,579 deaths occurred during the first year
of follow up. Among atorvastatin users, 45 emigrated
and 170 died during follow up whereof 24 emigrated
and 85 died within the first year after index date. About
half of simvastatin and atorvastatin users were women
(47.0% versus 45.4%), and a majority had Swedish back-
ground (83.2% versus 78.3%) (Table 1). The proportion
with a previous CVD diagnosis among simvastatin and
atorvastatin users was 23.2% and 17.1%, respectively.
The mean number of prescription drugs purchased one
year before an individual’s index date was 4.8 (SD 4.8) for
simvastatin users ( median = 4.0). For atorvastatin users,
the mean was 5.3 (SD 5.5) and the median 4.0. During
follow up, the mean number of generically substituted
statins was 2.6 (SD 2.2) for simvastatin users and 1.9
(SD 2.2) for atorvastatin users. The median was 2.0
and 1.0, respectively.Table 2 Mean values of CMA (95% confidence intervals) from
Unadjusted val
N M
Simvastatin users with generic substitution 100,995 86
Simvastatin users with active of generic substitution 801 72
Simvastatin users not exposed to generic substitution 7,010 52
Atorvastatin users 7,464 79
For those with generic substitution
Generic substitution at the first purchase 64,314 83
Generic substitution later on 36,681 92Refill adherence
For simvastatin, the mean CMA was 84.3% (SD 107.0),
with a median of 95.1%. For atorvastatin, the mean
CMA was 79.0% (SD 55.9), with a median of 85.0%.
Among simvastatin users, 92.8% were exposed to gen-
eric substitution during follow up, and 1.6% purchased
brand-name simvastatin products during follow up. The
adjusted mean value of CMA was significantly lower for
all individuals without generic substitution (i.e., groups
ii, iii, and iv together), compared to individuals who were
exposed to substitution [59.9% (95% CI 58.4-61.4) versus
84.6% (95% CI 83.5-85.6), p <0.001]. The adjusted mean
CMA was lowest among simvastatin users not exposed
to generic substitution [36.7 (95% CI 34.8-38.7)] (Table 2).
Furthermore refill adherence was significantly lower among
simvastatin users who actively refused generic substitution,
compared to simvastatin users exposed to generic substitu-
tion and atorvastatin users.
In the total study population, CMA was higher among
older individuals, individuals with previously diagnosed
CVD and type 2 diabetes medicines (Table 3). CMA was
significantly lower in individuals with migrant background,
compared to individuals with Swedish background.
Altogether, 10,673 simvastatin users and 848 atorva-
statin users filled their prescription only once. CMA was
somewhat higher after excluding such participants, but
the results did not change substantially (Table 4). CMA
did not increase among simvastatin users who were not
exposed to generic substitution. Comparing those who
switched between statins to those who did not, CMA
was higher for simvastatin users who actively refused
generic substitution and simvastatin users who did not
experience generic substitution; it was lower among
atorvastatin users (Table 4).
Adherence in relation to timing of generic substitution
CMA was lower among simvastatin users who were ex-
posed to generic substitution at first purchase, compared
to users who were exposed subsequently (Table 2). Among
those who were exposed to generic substitution, CMA
was significantly higher among older individuals, thoseANOVA and ANCOVA analyses
ues Adjusted values
ean (%) 95% CI n Mean (%) 95% CI
.6 86.1 – 87.1 82,532 84.6 83.5 – 85.6
.2 68.9 – 75.4 651 71.6 66.5 – 76.7
.8 45.8 – 59.8 5,590 36.7 34.8 – 38.7
.0 77.7 – 80.3 6,395 79.0 77.1 – 80.9
.5 82.7-84.2 80.4 79.4-90.9
.2 91.8-92.5 89.8 88.7-90.9
Table 3 Analysis of CMA by covariates in relation to
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Insulin only 0.0 1.0
Oral antidiabetics only, or both insulin
and oral antidiabetics
3.6 <.0001
Differences in continuous measure of medication acquisition (CMA) by
exposure to generic substitution by each covariate analysed with ANCOVA.
The first class of each covariate is used as a reference ( N = 95,168, whereof
88,773 new simvastatin users).
aData on educational level was not available for individuals 80 years and older.
Thus, this age group was excluded from the analysis.
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antidiabetic medicines, and individuals taking at least five
medications (Table 5). CMA was significantly lower among
individuals with migrant background, compared to individ-
uals with Swedish background.
Excluding those with only one statin purchase yielded
a smaller difference in CMA between those who experi-
enced generic substitution at first purchase and those
who did so later on (Table 4).Discussion
More than nine of ten new simvastatin users experi-
enced generic substitution during the follow up period.
Refill adherence was higher among individuals experiencing
substitution, comparing to those who did not. Simvastatin
users who actively declined substitution showed higher
refill adherence, compared to participants who accepted
substitution. Increasing age and statin use for secondary
prevention associated with higher refill adherence.
Adherence levels for simvastatin concurred with re-
sults from Denmark [1], but were lower than those re-
ported in a previous Swedish study [2], partly due to
different exclusion and inclusion criteria. The effects of
generic substitution on adherence are consistent with
previous quantitative [7,9,13] and qualitative [6] studies
reporting that generic substitution did not negatively
affect adherence level. A reason may be that individuals
who experience substitution may receive more attention
at the pharmacy [9]. However, few studies have assessed
the effects of generic substitution and other policy mea-
sures, and the potential for considerable differences be-
tween therapeutic areas requires further research. Refill
adherence does not measure actual intake of a drug,
making it relevant to combine adherence with other
measurements to further validate our findings. We chose
CMA to assess refill adherence because it depicts pos-
session of a pharmaceutical and has proven reliable in a
similar setting [2].
We defined generic substitution as receiving a product
other than that specified on the prescription. However, we
were unable to identify either the number of actual substi-
tutions or the number products dispensed during follow
up. Studies analysing differences in adherence to generics
and brand-name products concluded that receiving ge-
nerics did not in itself affect adherence level [7,14].
Because switching statins is part of clinical practice,
we did not exclude such patients, and we allowed them
to fill prescriptions for other statin substances subse-
quently, during follow up. We assessed whether switch-
ing affected refill adherence during sensitivity analyses.
Early discontinuation or non-initiation was neither a rea-
son for exclusion since excluding those who filled only
one prescription would overestimate refill adherence [15].
Factors other than generic substitution (e.g., side effects)
can explain early discontinuation and non-initiation [16]
and result in lower refill adherence. To assess such im-
pact, we included those factors in the sensitivity analyses,
which showed no evidence that non-initiation or early dis-
continuation affected the differences in refill adherence
estimates for those who did not experience generic
substitution. As expected, refill adherence increased
for the group exposed to generic substitution at the
index date. Also, by allowing switching between statins,
part of the discontinuation is handled. Prescriptions filled




Switching between different statins
≥ 2 filled statin
prescriptions
No switches 1-3 switches
N Mean (%) 95% CI N Mean (%) 95% CI N Mean (%) 95% CI
Entire study population
Simvastatin users with generic substitution 94525 90.1 89.9-90.3 93572 86.9 86.0-87.8 7423 83.1 82.0-84.1
Simvastatin users with active decline of generic substitution 697 79.8 84.7-86.8 533 68.1 56.4-79.9 268 80.2 74.6-85.7
Simvastatin users not exposed to generic substitution 2911 52.5 76.6-83.0 5651 49.3 45.7-52.9 1292 75.9 73.4-78.5
Atorvastatin users 6616 85.8 50.9-54.0 6172 79.6 76.2-83.1 1359 67.0 64.6-69.5
Those with generic substitution
Generic substitution at first purchase 57844 88.7 88.4-89.1 59175 83.7 83.0-84.4 5139 80.7 79.6-81.8
Generic substitution later on 36681 92.2 91.8-92.5 34297 92.4 91.4-93.4 2284 88.4 86.8-90.1
Trusell and Andersson Sundell BMC Health Services Research 2014, 14:626 Page 6 of 8
http://www.biomedcentral.com/1472-6963/14/626close to date of death or emigration increase adherence.
Previous studies suggested that simultaneous intake of
multiple products with the same active ingredient could
increase after generic substitution [5] which would hence
increase refill adherence. This would also apply to individ-
uals using combination treatment (i.e., prescribing two
different-strength tablets). However, such scenarios are
unclear in the present data.
We selected new statin users to ensure a uniform study
population, where previously developed adherence pat-
terns to statin treatment would not influence the adher-
ence estimate. Thus, we were able to isolate the effects of
generic substitution to greater extent. We imposed a
12-month washout period because Swedish prescrip-
tions are valid for one year. Our study group assigned
new atorvastatin users to an unexposed control group
because atorvastatin was not substitutable during the
study period. Both substances were included in the PBS
during the study period although atorvastatin had limited
reimbursement since Swedish therapeutic guidelines
recommended simvastatin as first-line therapy. Atorva-
statin was recommended when simvastatin failed to
achieve treatment goals or was inappropriate for other
reasons. Although treatment indications are similar, given
the therapeutic guidelines, atorvastatin users may have
more severe problems. In Sweden there is no approval
process for prescribing medicines with limited reimburse-
ment provided within the PBS. However, our comparison
of background characteristics and medical history could
not confirm this, there was similarity of socioeconomic
characteristics between simvastatin and atorvastatin users
and the presence of pharmacologically treated diabetes.
The proportion of pre-existing CVD was higher among
simvastatin users, suggesting that statin use for sec-
ondary prevention of CVD was more common for sim-
vastatin than atorvastatin. However, selection bias might
influence whether an individual received a simvastatin oratorvastatin prescription. Although atorvastatin lacks gen-
eric equivalents, parallel imported drugs were available,
and these products are often identical and not regarded as
substitution.
We excluded individuals younger than 18 years and
those who received multi-dose dispensed drugs because
they are not always in charge of their own medication.
Further, multi-dose drugs are automatically dispensed at
regular intervals, creating an artificial adherence pattern
and were therefore excluded. Due to the construction of
the Swedish PBS [11], stockpiling can occur, contribut-
ing to higher CMA. We imposed a two-year follow-up
period to reduce the effects of stockpiling.
We were unable to examine primary non-adherence
(i.e., not initiating treatment) because SPDR records
only dispensed prescriptions, not issued prescriptions.
In Sweden primary non-adherence varies from 1.5%
for cardiovascular drugs in general to around 7%–8%
for statins among stroke patients, based on electronic
prescriptions [17,18].
The National Patient Register covers secondary health
care, but limits coverage for diagnoses commonly han-
dled in primary care, such as diabetes. Therefore, we
used purchased anti-diabetic drugs as a proxy variable
for pharmacologically treated diabetes. By separating in-
dividuals using dispensed insulin or oral anti-diabetics
and those using both, we attempted to distinguish be-
tween individuals with type 1 and type 2 diabetes. How-
ever, the insulin treatment group included individuals
with both types of diabetes. Many patients with diabetes
type 2 are treated non-pharmacologically [19], this is
thus not a suitable proxy for diabetes itself.
To identify individuals who received statins as second-
ary prevention, we used most recent guidelines diagnosis
codes from the National Patient Register. Importantly,
contact with a healthcare provider does not always gener-
ate a diagnosis. Therefore, a more comprehensive indicator
Table 5 Analysis of CMA by covariates in relation to
timing of generic substitution among those who















Primary school (reference) –















Insulin only −1.2 0.2
Oral antidiabetics only or both insulin
and oral antidiabetics
3.7 <.0001
Differences in continuous measure of medication acquisition (CMA) for those
who experienced generic substitution at first purchase, compared to
subsequent substitution by each covariate, analysed with ANCOVA. The first
class of each covariate is used as a reference (N = 82,532).
aData on educational level was not available for individuals 80 years and older.
Thus, this age group was excluded from the analysis.
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reviewing patient’s medical records and combining diag-
noses with data about health procedures (e.g., stents). Be-
cause the Patient Register did not include full coverage of
procedures during the study period, we were unable to
make a determination in this regard. Generic simvastatin
is relatively inexpensive. Thus, employment status and
income level are less likely to affect results and were
not included in our analysis.Conclusions
Measured using CMA, mean values of refill adherence
to simvastatin and atorvastatin were 84.3% and 79.0%,
respectively. Most simvastatin users experienced generic
substitution sometime during the study period, and refill
adherence was highest among those who had experienced
generic substitution. Certain patient characteristics affected
adherence level. In particular, refill adherence increased
with age and among individuals who had experienced a
cardiovascular event. Patients’ concerns about generic
substitution may require more information from the
prescriber and at the pharmacy.
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